European Alliance of Associations for Rheumatology (EULAR) 2021

Relationship of Anifrolumab PK with Efficacy and Safety in Patients with SLE

Characterization of PK/PD of Anifrolumab in Patients with Moderate to Severe SLE

Novel Stringent Outcomes Measures Applied to the Phase 2 and 3 Anifrolumab Trials

Randomized, Controlled, Phase 2 Trial of Type 1 IFN Inhibitor Anifrolumab in Patients with Active Proliferative Lupus Nephritis 

Anifrolumab Effects on Rash and Arthritis in Patients with SLE and Impact of Interferon Signal in Pooled Data from Phase 3 Trials

Effects of Anifrolumab on Renal Disease in Patients with SLE

Patient Reported Physical Health Compared to Clinician Recorded BILAG-2004 Muscoloskeletal System Scores - Discordance Between Patients with Clinicians 

AZD9567 versus Prednisolone in Patients with Active Rheumatoid Arthritis: A Phase 2a, Randomized, Double-Blind, Parallel-Group Efficacy and Safety Study

Short-term risk of osteoporosis in adults treated with corticosteroids: an observational study.